DARE Dare Bioscience, Inc.
Listings ·
Daré Bioscience has until March 29, 2027 to show a $1.00 closing bid price for 10 consecutive business days. A second 180-day period is possible only if it meets the other listing standards and says it will cure the shortfall, by a reverse split if needed. Its cash fell to $12.6 million by June 30, 2026.
Daré Bioscience sold 4.38M shares at $1.37 and gave buyers two warrant series covering 8.76M more, while Nasdaq reviews its listing and cash runs into Q4.
Nasdaq told Daré Bioscience (Nasdaq: DARE) on July 13, 2026 that it no longer meets Listing Rule 5550(b). The company intends to request a hearing, which would stay delisting while the panel decides.
Daré issued 20,000 Investor Units at $5.00 each, with one Series A Convertible Preferred share and two warrants per unit. The offering is for up to 4,854,000 units, and the company's auditor has raised going concern doubt.
Daré Bioscience, Inc. is a purpose-driven health biotech company focused on women's health, with programs covering contraception, menopause, pelvic pain, fertility, vaginal health and infectious disease. For select proprietary formulations it pursues both traditional FDA approval and earlier market access through outsourcing facilities registered under Section 503B of the FDCA. In December 2025 it began commercialization of DARE to PLAY Sildenafil Cream, a topically applied sildenafil formulation designed to improve female sexual arousal. Its first DARE to RESTORE product, Flora Sync LF5, a vaginal probiotic suppository, is expected to become commercially available in the U.S. in the second quarter of 2026. Its first FDA-approved product, XACIATO (clindamycin phosphate) vaginal gel 2%, was approved in December 2021 for bacterial vaginosis. Organon licensed worldwide rights to XACIATO in 2022, and in April 2024 Daré sold its rights to royalty and milestone payments on XACIATO net sales to XOMA (US) LLC. Its most advanced candidates include Ovaprene, a hormone-free monthly intravaginal contraceptive in a pivotal Phase 3 study, and DARE-HRT1, an intravaginal ring for menopausal hormone therapy. The company does not intend to build its own sales force.
| Product or program | What it is | Stage |
|---|---|---|
| Ovaprene | Hormone-free monthly intravaginal contraceptive | pivotal Phase 3 clinical study |
| DARE to PLAY Sildenafil Cream | 3.6% topical sildenafil cream for female sexual arousal | commercialization initiated December 2025 |
| Flora Sync LF5 | Vaginal probiotic suppository in the DARE to RESTORE line | expected commercially available in the U.S. in second quarter 2026 |
| DARE-HRT1 | Intravaginal ring delivering estradiol and progesterone for hot flashes | |
| XACIATO | Clindamycin phosphate vaginal gel 2% for bacterial vaginosis | approved in the US |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.5 million | $14.3 million |
| Net income (loss) | -$13.4 million | -$4.1 million |
| Cash from operations | -$9.9 million | $5.5 million |
| Cash and equivalents | $24.7 million | $15.7 million |
Our latest story on this, dated Oct 2, 2026: "Daré Bioscience gets Nasdaq notice for stock below $1.00". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 17, 2026: "Daré Bioscience gets Nasdaq notice on stockholders' equity, plans hearing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 20, 2026: "Daré Bioscience closes sale of 20,000 units in Regulation A preferred stock and warrant offering". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Daré prices $6.0M registered direct with warrants on twice the shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 20, 2026: "Daré Bioscience closes sale of 20,000 units in Regulation A preferred stock and warrant offering". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 2, 2026: "Daré Bioscience gets Nasdaq notice for stock below $1.00". The story links the filing or release it is based on. Read the story.
Dare Bioscience, Inc. trades under the ticker DARE on NASDAQ.
Dare Bioscience, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Dare Bioscience, Inc. is 1401914. Its filings are on SEC EDGAR.
15,289,502 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Dare Bioscience, Inc. under United States.
Our directory classifies Dare Bioscience, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Dare Bioscience, Inc. is US23666P2002.
aibio.space lists Dare Bioscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.03,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio